Clinical Edge Journal Scan

Some patients with resistant chronic migraine may derive long-term benefits with erenumab


Key clinical point: Monthly erenumab demonstrated promising short-term clinical effectiveness in patients with difficult-to-treat chronic migraine; however, less than one-fourth of the patients sustained efficacy over 2 years.

Major finding: The monthly migraine days (MMD) reduced significantly after 6 months of erenumab treatment (mean reduction [MR] 7.5 days; P < .001), with 48% of patients achieving ≥30% reduction in MMD. At months 12 and 24, 38% and 23% of patients remained ≥30% responders, respectively.

Study details: Findings are from a 2-year real-world prospective analysis of a clinical audit including 160 patients with difficult-to-treat chronic migraine who failed an average of 8.3 preventive treatments and received monthly erenumab.

Disclosures: This study did not receive any funding. Three authors declared receiving honoraria for speaking or participation in advisory boards or funding for travel from various sources.

Source: Andreou AP et al. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain. 2022;23:139 (Nov 4). Doi: 10.1186/s10194-022-01507-8

Recommended Reading

Commentary: Risk factors and treatment for pediatric migraine, December 2022
Migraine ICYMI
High drug costs exclude most neurology patients from cutting-edge treatment
Migraine ICYMI
Evidence supporting atogepant as a promising treatment for migraine prevention
Migraine ICYMI
Alcohol as a trigger for migraine: What is the link?
Migraine ICYMI
Prior proton-pump inhibitor use ups migraine risk
Migraine ICYMI